Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
2.340
-0.130 (-5.26%)
Nov 5, 2025, 4:00 PM EST - Market closed
Lisata Therapeutics Revenue
Lisata Therapeutics had revenue of $70.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $1.07M. In the year 2024, Lisata Therapeutics had annual revenue of $1.00M.
Revenue (ttm)
$1.07M
Revenue Growth
n/a
P/S Ratio
18.55
Revenue / Employee
$41,154
Employees
26
Market Cap
20.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LSTA News
- 1 day ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 6 days ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire
- 23 days ago - Lisata Therapeutics to Present at LD Micro Main Event XIX - Newsfile Corp
- 4 weeks ago - Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement - GlobeNewsWire
- 5 weeks ago - Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial - GlobeNewsWire
- 2 months ago - Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire